Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
264 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015', provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Chronic Lymphocytic Leukemia (CLL) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsed Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Relapsed Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview 9 Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 10 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 13 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 17 Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 20 Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 21 4SC AG 21 AbbVie Inc. 22 Astellas Pharma Inc. 23 Astex Pharmaceuticals, Inc. 24 AstraZeneca Plc 25 Boehringer Ingelheim GmbH 26 Bristol-Myers Squibb Company 27 Celgene Corporation 28 Cyclacel Pharmaceuticals, Inc. 29 Emergent BioSolutions Inc. 30 F. Hoffmann-La Roche Ltd. 31 Gilead Sciences, Inc. 32 Hutchison MediPharma Limited 33 ImmunoGen, Inc. 34 Immunomedics, Inc. 35 Incyte Corporation 36 Infinity Pharmaceuticals, Inc. 37 Innate Pharma SA 38 Juno Therapeutics Inc. 39 Karyopharm Therapeutics, Inc. 40 Les Laboratoires Servier SAS 41 LFB S.A. 42 Lymphocyte Activation Technologies, S.A. 43 MedImmune, LLC 44 Millennium Pharmaceuticals, Inc. 45 MorphoSys AG 46 Novartis AG 47 Ono Pharmaceutical Co., Ltd. 48 Portola Pharmaceuticals, Inc. 49 Sanofi 50 TG Therapeutics, Inc. 51 Threshold Pharmaceuticals, Inc. 52 Tragara Pharmaceuticals, Inc. 53 Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Combination Products 55 Assessment by Target 56 Assessment by Mechanism of Action 59 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 (INCB-039110 + INCB-040093) - Drug Profile 66 4SC-202 - Drug Profile 67 acalabrutinib - Drug Profile 69 ACP-319 - Drug Profile 72 afuresertib hydrochloride - Drug Profile 73 AGS-67E - Drug Profile 75 AT-7519 - Drug Profile 76 AZD-6738 - Drug Profile 79 BI-836826 - Drug Profile 81 BMS-986016 - Drug Profile 82 buparlisib hydrochloride - Drug Profile 83 CC-122 - Drug Profile 87 Cellular Immunotherapy for Chronic Lymphocytic Leukemia - Drug Profile 89 Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile 90 cerdulatinib - Drug Profile 91 duvelisib - Drug Profile 92 evofosfamide - Drug Profile 95 GS-9901 - Drug Profile 103 HMPL-523 - Drug Profile 104 IMGN-529 - Drug Profile 105 IMMU-114 - Drug Profile 107 inebilizumab + rituximab - Drug Profile 108 IPH-2201 - Drug Profile 109 JCAR-014 - Drug Profile 111 JCAR-015 - Drug Profile 112 lirilumab - Drug Profile 114 MOR-208 - Drug Profile 116 nivolumab - Drug Profile 118 obinutuzumab - Drug Profile 126 otlertuzumab - Drug Profile 129 pilaralisib - Drug Profile 131 S-055746 - Drug Profile 134 sapacitabine - Drug Profile 135 selinexor - Drug Profile 137 spebrutinib besylate - Drug Profile 143 TAK-659 - Drug Profile 145 TG-02 - Drug Profile 146 TGR-1202 - Drug Profile 149 tisagenlecleucel-T - Drug Profile 151 trametinib dimethyl sulfoxide - Drug Profile 154 ublituximab - Drug Profile 157 ublituximab + TGR-1202 - Drug Profile 159 UC-961 - Drug Profile 160 ulocuplumab - Drug Profile 161 urelumab - Drug Profile 163 venetoclax - Drug Profile 165 Relapsed Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 168 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 248 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 249 Relapsed Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 250 Featured News & Press Releases 250 Appendix 259 Methodology 259 Coverage 259 Secondary Research 259 Primary Research 259 Expert Panel Validation 259 Contact Us 259 Disclaimer 260
List of Tables
Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL), H2 2015 13 Number of Products under Development for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2015 14 Number of Products under Development by Companies, H2 2015 16 Number of Products under Investigation by Universities/Institutes, H2 2015 17 Comparative Analysis by Late Stage Development, H2 2015 18 Comparative Analysis by Clinical Stage Development, H2 2015 19 Comparative Analysis by Early Stage Development, H2 2015 20 Products under Development by Companies, H2 2015 21 Products under Development by Companies, H2 2015 (Contd..1) 22 Products under Development by Companies, H2 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H2 2015 24 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2015 25 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H2 2015 26 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2015 27 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 28 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H2 2015 29 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2015 30 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2015 31 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2015 32 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2015 33 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H2 2015 34 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 35 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2015 36 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2015 37 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2015 38 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2015 39 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2015 40 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 41 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H2 2015 42 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2015 43 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 44 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H2 2015 45 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2015 46 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2015 47 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H2 2015 48 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 49 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2015 50 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2015 51 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 52 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 53 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2015 54 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H2 2015 55 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015 56 Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2015 57 Assessment by Monotherapy Products, H2 2015 58 Assessment by Combination Products, H2 2015 59 Number of Products by Stage and Target, H2 2015 61 Number of Products by Stage and Mechanism of Action, H2 2015 64 Number of Products by Stage and Route of Administration, H2 2015 67 Number of Products by Stage and Molecule Type, H2 2015 69 Relapsed Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H2 2015 172 Relapsed Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2015 252 Relapsed Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2015 253
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
